Moderna-Merck mRNA Vaccine Phase 3 Win

Moderna and Merck announced that their personalized mRNA-based melanoma cancer vaccine (mRNA-4157/V940, co-developed with Keytruda) met its primary endpoint in a pivotal Phase 3 trial — the first individualized mRNA cancer vaccine to succeed at this stage. This is a landmark result because it validates the broader mRNA therapeutic platform beyond infectious disease and substantially de-risks the oncology pipeline that Moderna has been betting its post-COVID future on. Moderna shares have surged roughly 90-93% on the news, and Merck shares are up approximately 7%, reflecting both the commercial potential of a new cancer treatment category and the licensing economics. Positioning: long MRNA for continued momentum and potential further re-rating as analysts update oncology pipeline valuations; long MRK as the Keytruda franchise gets extended into a novel adjuvant modality; watch for sympathy moves in mRNA platform peers like BioNTech.